Citations

Mayo Clinic

Showing 10 of 108523 citations.

Quantitative analysis of three-dimensional fibrillar collagen microstructure within the normal, aged and glaucomatous human optic nerve head
Jones, Hannah , Girard, Michaël J. A. , Fautsch, Michael P. , Morgan, James P. , Ethier, C. Ross , Albon, Julie , Albon, J , White, Neil M.

Journal of The Royal Society Interface | March 25, 2015 | Volume: 12 | Issue: 106 | Pages: 20150066

10.1098/rsif.2015.0066 | PMID 25808336 Get It

The aim of this study was to quantify connective tissue fibre orientation and alignment in young, old and glaucomatous human optic nerve heads (ONH) to understand ONH microstructure and predisposition to glaucomatous optic neuropathy. Transverse (seven healthy, three glaucomatous) and longitudinal (14 healthy) human ONH cryosections were imaged by both second harmonic generation microscopy and small angle light scattering (SALS) in order to quantify preferred fibre orientation (PFO) and degree of fibre alignment (DOFA). DOFA was highest within the peripapillary sclera (ppsclera), with relatively low values in the lamina cribrosa (LC). Elderly ppsclera DOFA was higher than that in young ppsclera ( p < 0.00007), and generally higher than in glaucoma ppsclera. In all LCs, a majority of fibres had preferential orientation horizontally across the nasal–temporal axis. In all glaucomatous LCs, PFO was significantly different from controls in a minimum of seven out of 12 LC regions ( p < 0.05). Additionally, higher fibre alignment was observed in the glaucomatous inferior–temporal LC ( p < 0.017). The differences between young and elderly ONH fibre alignment within regions suggest that age-related microstructural changes occur within the structure. The additional differences in fibre alignment observed within the glaucomatous LC may reflect an inherent susceptibility to glaucomatous optic neuropathy, or may be a consequence of ONH remodelling and/or collapse.
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation
Hoskote, Sumedh S. , Reddy, D. Rajasekhar, Onigkeit, James A., Reddy, D. R. S.

Transfusion Medicine | March 25, 2015 | Volume: 25 | Issue: 2 | Pages: 118-121

10.1111/tme.12191 | PMID 25808255 Get It

Future directions in urological oncology
Thompson, R. Houston

BJU International | March 25, 2015 | Volume: 115 | Issue: 4 | Pages: 499-499

10.1111/bju.13076 | PMID 25808707 Get It

The association between sleep disturbances and alcohol relapse: A 12-month observational cohort study
Kolla, Bhanu Prakash , Schneekloth, Terry D. , Mansukhani, Meghna P. , Hall‐Flavin, Daniel K., Karpyak, Victor M. , Geske, Jennifer R. , Frye, Mark A. , Biernacka, Joanna M. , Kolla, Bhanuprakash , Mansukhani, Meghna P , Karpyak, Victor , Geske, Jennifer

The American Journal on Addictions | March 24, 2015 | Volume: 24 | Issue: 4 | Pages: 362-367

10.1111/ajad.12199 | PMID 25808396 Get It

Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci
Coetzee, Simon G. , Shen, Howard C., Hazelett, Dennis J. , Lawrenson, Kate , Kuchenbaecker, Karoline , Rhie, Suhn K. , Levanon, Keren , Karst, Alison M., Drapkin, Ronny , Ramus, Susan J. , Offit, Kenneth, Chenevix‐Trench, Georgia , Monteiro, Álvaro N.A. , Antoniou, Antonis C. , Freedman, Matthew L., Coetzee, Gerhard A. , Gayther, Simon A. , Antonenkova, Natalia, Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Bruinsma, Fiona , Chang‐Claude, Jenny, Chen, Ann , Chen, Zhihua , Cunningham, Julie M. , Dansonka‐Mieszkowska, Agnieszka , Dicks, Ed , Dörk, Thilo , Eccles, Diana , Easton, Douglas F. , Edwards, Robert P., Eilber, Ursula, Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Giles, Graham G. , Glasspool, Rosalind , Goode, Ellen L. , Grownwald, Jacek, Harrington, Patricia, Harter, Philipp , Hasmad, Hanis Nazihah, Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Claus , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , James, Paul A. , Jensen, Allan , Ji, Bu‐Tian , Kjær, Susanne K. , Kelemen, Linda E. , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Krakstad, Camilla , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Lissowska, Jolanta , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, Valerie , McLaughlin, John R., McNeish, Ian, Menon, Usha , Moysich, Kirsten B., Narod, Steven A., Nedergaard, Lotte , Ness, Roberta B., Azmi, Mat Adenan Noor, Odunsi, Kunle , Oršulić, Sandra , Pearce, Celeste Leigh, Pelttari, Liisa M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Pike, Malcolm C., Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B., Rzepecka, Iwona K. , Salvesen, Helga B., Schildkraut, Joellen M. , Schwaab, Ira, Sellers, Thomas A. , Shu, Xiao‐Ou, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Sucheston, Lara, Tangen, Ingvild L. , Teo, Soo‐Hwang , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anne M. van , Nieuwenhuysen, Els Van , Vergote, Ignace , Vierkant, Robert A. , Wang‐Gohrke, Shan , Walsh, Christine , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Woo, Yin Ling , Wu, Xifeng , Wu, Anna H. , Lu, Karen H. , McNeish, Iain A. , Lambrechts, Diether , Tyrer, Jonathan P. , Couch, Fergus J. , Pharoah, Paul D.P. , Noushmehr, Houtan , Anton‐Culver, Hoda , Baker, Helen H. , Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Campbell, Ian , Carty, Karen , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Goodman, Marc T. , Hildebrandt, Michelle A.T. , Høgdall, Estrid , Karlan, Beth Y. , Lester, Jenny, Liang, Dong , Lu, Karen, McLaughlin, John R., McNeish, Ian, Modugno, Francesmary , Olson, Sara H. , Orlow, Irene , Weber, Rachel Palmieri , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rosen, Barry P. , Rudolph, Anja , Siddiqui, Nadeem , Terry, Kathryn L. , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Zheng, Wei , Ziogas, Argyrios , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , James, Paul , Kiemeney, Lambertus A , Kjaer, Susanne K , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Hazelett, Dennis J , Coetzee, Simon G , Monteiro, Alvaro N , Lissowska, Jolanta , Southey, Melissa C , Glasspool, Rosalind , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Drapkin, Ronny , Høgdall, Claus K , Lubinski, Jan

Human Molecular Genetics | March 24, 2015 | Volume: 24 | Issue: 13 | Pages: 3595-3607

10.1093/hmg/ddv101 | PMID 25804953 Get It

APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons
Woodruff, Bryan K. , Acosta, Jazmin I., Locke, Dona E.C. , Hentz, Joseph G. , Stonnington, Cynthia M. , Stokin, Gorazd B. , Nagle, Chelsea, Michel, Bernard François, Sambuchi, Nathalie, Caselli, Richard J. , Geda, Yonas E. , Krell-Roesch, Janina, Locke, Dona E, Michel, Bernard F, Krell‐Roesch, Janina , Geda, Yonas E , Locke, Dona E C , Stokin, Gorazd

The Journal of Neuropsychiatry and Clinical Neurosciences | March 24, 2015 | Volume: 27 | Issue: 4 | Pages: 322-325

10.1176/appi.neuropsych.14100268 | PMID 25803305 Get It

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
Seggewiß-Bernhardt, Ruth , Bargou, Ralf C. , Stewart, A. Keith, Spencer, Andrew , Alegre, Adrían , Bladé, Joan , Ottmann, Oliver G. , Fernandez‐Ibarra, Cristina, Lü, Hong , Pain, Scott, Iyer, Swaminathan P. , Goh, Yeow Tee , Akimov, Mikhail

Cancer | March 24, 2015 | Volume: 121 | Issue: 13 | Pages: 2185-2192

10.1002/cncr.29339 | PMID 25809731 Get It

BACKGROUNDNVP‐AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells. This phase 1/1B study assessed NVP‐AUY922 alone and with bortezomib in patients with relapsed or refractory MM.METHODSDose escalation was guided by an adaptive Bayesian logistic regression model. In phase 1, patients who progressed after 2 to 4 prior therapies received NVP‐AUY922 intravenously once weekly. In phase 1B, patients who progressed after 2 or fewer prior therapies received NVP‐AUY922 plus bortezomib. The primary objective was to determine the maximum tolerated dose (MTD) of NVP‐AUY922.RESULTSTwenty‐four patients received NVP‐AUY922 monotherapy at doses of 8 to 70 mg/m2. One dose‐limiting toxicity (DLT) was observed (grade 3 blurred vision at 70 mg/m2); no MTD was reached. The recommended phase 2 dose was 70 mg/m2. The most frequent drug‐related adverse events (AEs) were diarrhea, nausea, and ocular toxicities. Grade 3/4 AEs were uncommon (<10%). Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (≥45 mg/m2). The best response was stable disease in 66.7% of the patients. There were no partial or complete responses. Five patients received NVP‐AUY922 (which was started at 50 mg/m2) plus bortezomib (1.3 mg/m2). Three of these patients experienced DLT. No further dose escalation was performed; the MTD for NVP‐AUY922 plus bortezomib was not established.CONCLUSIONSThis study showed disease stabilization with NVP‐AUY922 in patients with relapsed or refractory MM. The MTD for NVP‐AUY922 was not reached, but reversible ocular toxicity has been reported at high dose levels. Bortezomib at the standard recommended dose plus NVP‐AUY922 was not tolerated. Cancer 2015;121:2185–2192. © 2015 American Cancer Society.
Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management
Gertz, Morie A.

American Journal of Hematology | March 24, 2015 | Volume: 90 | Issue: 4 | Pages: 346-354

10.1002/ajh.23922 | PMID 25808108 Get It

Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity.Diagnosis: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients.Risk Stratification: Age, hemoglobin level, platelet count, β2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis.Risk‐Adapted Therapy: Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐based therapy is used in virtually all US patients with WM and can be combined with alkylating agent or purine nucleoside analog (or both). The preferred Mayo Clinic nonstudy therapeutic induction is rituximab, cyclophosphamide, and dexamethasone. Future stem cell transplantation should be considered in induction therapy selection.Management of Refractory Disease: Bortezomib, thalidomide, everolimus, ibrutinib, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in WM. Given WM's natural history, reduction of complications will be a priority for future treatment trials. Am. J. Hematol. 90:347–354, 2015. © 2015 Wiley Periodicals, Inc.
Molecularly Engineered Biodegradable Polymer Networks with a Wide Range of Stiffness for Bone and Peripheral Nerve Regeneration
Wang, Shanfeng , Ruiter, Godard C. W. de , Spinner, Robert J. , Windebank, Anthony J. , Yaszemski, Michael J. , Lu, Lichun , Kempen, Diederik H.R. , Cai, Lei

Advanced Functional Materials | March 24, 2015 | Volume: 25 | Issue: 18 | Pages: 2715-2724

10.1002/adfm.201500105 Get It

To satisfy different mechanical requirements in hard and soft tissue replacements, a series of biodegradable and crosslinkable copolymers of poly(propylene fumarate)‐co‐polycaprolactone (PPF‐co‐PCL) are synthesized and employed to fabricate 2D disks and 3D scaffolds via photocrosslinking. Thermal properties such as the glass transition temperature (Tg) and melting temperature (Tm) of the PPF‐co‐PCL networks can be controlled efficiently by varying the PCL composition (φPCL). As a result, their mechanical properties vary significantly from hard and stiff materials to soft and flexible ones with increasing φPCL, making them attractive candidate materials for bone and peripheral nerve regeneration, respectively. Several PPF‐co‐PCL formulations are selected to perform in vitro cell studies using mouse pre‐osteoblastic MC3T3‐E1, rat Schwann cell precursor line (SPL201), and pheochromocytoma (PC12) cells, and in vivo animal testing in the rat femur bone defect model and in the rat sciatic nerve transection model. The formation of new bone in the porous bone scaffolds with a low φPCL and guided axon growth through the nerve conduits with a higher φPCL suggest that crosslinked PPF‐co‐PCLs have appropriate compatibility and functionality. Furthermore, the role of surface stiffness in modulating cellular behavior and functions is verified on the crosslinked PPF‐co‐PCL surfaces without any pretreatments.
The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation
Wu, Qiong , Madany, Pasil, Akech, Jacqueline, Dobson, Jason R. , Douthwright, Stephen, Browne, Gillian , Colby, Jennifer L., Bradner, James E. , Pratap, Jitesh , Sluder, Greenfield, Chiosea, Simion I. , Wijnen, André J. van , Stein, Janet L. , Stein, Gary S., Lian, Jane B. , Nickerson, Jeffrey A. , Imbalzano, Anthony N. , van Wijnen, Andre J, Winter, Georg E. , Bhargava, Rohit , van Wijnen, Andre J

Journal of Cellular Physiology | March 24, 2015 | Volume: 230 | Issue: 11 | Pages: 2683-2694

10.1002/jcp.24991 | PMID 25808524 Get It

The Brahma (BRM) and Brahma‐related Gene 1 (BRG1) ATPases are highly conserved homologs that catalyze the chromatin remodeling functions of the multi‐subunit human SWI/SNF chromatin remodeling enzymes in a mutually exclusive manner. SWI/SNF enzyme subunits are mutated or missing in many cancer types, but are overexpressed without apparent mutation in other cancers. Here, we report that both BRG1 and BRM are overexpressed in most primary breast cancers independent of the tumor's receptor status. Knockdown of either ATPase in a triple negative breast cancer cell line reduced tumor formation in vivo and cell proliferation in vitro. Fewer cells in S phase and an extended cell cycle progression time were observed without any indication of apoptosis, senescence, or alterations in migration or attachment properties. Combined knockdown of BRM and BRG1 showed additive effects in the reduction of cell proliferation and time required for completion of cell cycle, suggesting that these enzymes promote cell cycle progression through independent mechanisms. Knockout of BRG1 or BRM using CRISPR/Cas9 technology resulted in the loss of viability, consistent with a requirement for both enzymes in triple negative breast cancer cells. J. Cell. Physiol. 9999: 2683–2694, 2015. © 2015 Wiley Periodicals, Inc.